CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 352 enrolled
Drug / intervention
Progesterone vaginal ringdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03565211
NCT03565211Phase 3Completed

A Prospective, Multi-Center, Non-Comparative Trial of the Clinical Safety of the Progesterone Vaginal Ring in Women Undergoing Assisted Reproductive Technology (ART) Procedures

Ferring Pharmaceuticals·interventional·Posted Jun 21, 2018·Updated Nov 23, 2020

In Brief

A Phase 3 clinical trial evaluating Progesterone vaginal ring for Progesterone Supplementation in Women Undergoing ART. Completed, enrolled 352 participants across 15 sites.

Detailed Summary

The purpose of the study is to assess the safety of Progesterone Vaginal Ring (PVR) in women undergoing fresh embryo transfer (ART).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States
Collaborators--

Timeline

Phase 3CompletedFinished
20192020202120222023202420252026
First PostedJun 21, 2018
Enrollment StartJul 26, 2018
Primary CompletionJul 29, 2019
TodayJul 2, 2026
Enrollment to primary: 1.0 yearsPosted 8.0 years ago

Interventions

Progesterone vaginal ringdrug

A flexible, non-degradable PVR containing progesterone in micronized formulation and dispersed evenly throughout the ring.